Grand Rapids oncologist says experimental pancreatic cancer drug showing promise in trials offers hope
Clinical trials for an experimental pill called Daraxonrasib indicate improved survival rates for patients with advanced pancreatic cancer. The drug targets KRAS master switches to extend life expectancy. Medical professionals in Grand Rapids and Chattanooga report that these results offer new hope for treating the disease.
What changed
New trial data indicates Daraxonrasib nearly doubled median survival for pancreatic cancer patients.
Live updates
-
Experimental Drug Daraxonrasib Shows Survival Gains for Pancreatic Cancer
confidence 85%Clinical trials for an experimental pill called Daraxonrasib indicate improved survival rates for patients with advanced pancreatic cancer. The drug targets KRAS master switches to extend life expectancy. Medical professionals in Grand Rapids and Chattanooga report that these results offer new hope for treating the disease.
What's confirmed:
- Daraxonrasib is an experimental drug for pancreatic cancer.
- The drug targets KRAS pancreatic cancer.
- Trial results showed a nearly doubled median survival of 13.2 months compared to 6.7 months.
- The drug is designed as a pill for patients with advanced pancreatic cancer.
Still unconfirmed:
- More than half of people with pancreatic cancer die within three months of diagnosis.